Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE The knockdown of LXR protected against steatosis but failed to change phosphorylated AMPK. 30972177 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE Our data provided new evidence supporting the preventive role of 500 mg/(kg·bw·day) APE treatment in the HFD-induced hepatic steatosis in C57BL/6 mice via the LKB1/AMPK pathway. 31608624 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE These findings revealed that diminished AMPK/TFEB-dependent autophagy is involved in the pathogenesis of liver steatosis in obesity, and that CAT might be a novel therapeutic candidate for treatment of this condition. 31697646 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 AlteredExpression disease BEFREE Interestingly, activation of AMPK by metformin causes an augmentation of Insig stability and reduction of lipogenic gene expression, and leads to the attenuation of hepatic steatosis in HFHS diet-fed mice. 30733434 2019
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 AlteredExpression disease BEFREE In addition, DHA-induced activations of G<sub>q/11</sub> proteins, CaMKK, and AMPK were found to be signaling components of the steatosis protective pathway. 29126901 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 AlteredExpression disease BEFREE Our results suggest that serine supplementation could prevent HF diet-induced oxidative stress and steatosis by epigenetically modulating the expression of glutathione synthesis-related genes and through AMPK activation. 29158183 2018
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE Apelin protects against liver X receptor-mediated steatosis through AMPK and PPARα in human and mouse hepatocytes. 28821440 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE Our results demonstrate that AS-IV attenuates FFA-induced ER stress and lipid accumulation in an AMPK-dependent manner in hepatocytes, which supports its use as promising therapeutics for hepatic steatosis. 28344322 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient mice. 29092796 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE Pectic Bee Pollen Polysaccharide from Rosa rugosa Alleviates Diet-Induced Hepatic Steatosis and Insulin Resistance via Induction of AMPK/mTOR-Mediated Autophagy. 28452943 2017
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE These results provide new insights into the negative regulation of miR-451 in fatty acid-induced inflammation via the AMPK/AKT pathway and demonstrate potential therapeutic applications for miR-451 in preventing the progression from simple steatosis to severely advanced liver disease. 25957914 2015
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of steatosis and steatohepatitis. 24486702 2014
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE Taken together, these results indicate that MIF is highly expressed in the liver during physical exercise and may prevent hepatic steatosis by activating the AMPK pathway. 23823021 2013
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 Biomarker disease BEFREE Furthermore, fAd also showed suppression of palmitate-induced fetuin-A through the AMPK pathway and improvement of steatosis accompanied by restoration of SREBP-1c, PAPR-α and CD36. 23948064 2013
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.100 AlteredExpression disease BEFREE AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. 21459323 2011